Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

Maximum Purchase:
1 unit
Publication Date:
November 2018
Adding to cart… The item has been added

The biologics competitive landscape is at a critical stage of development. How will you respond?

Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete with AbbVie's blockbuster Humira, market dynamics have just ramped up another gear. That brings biologics life cycle management strategies to the fore, both for companies with proprietary biologics assets under threat and for biosimilar challengers looking to ensure a sustainable business.

Whatever stance you take in the biologics market–originator, biosimilar manufacturer, or even both–this report provides the most current commentary on the key players in biologics life cycle management, including competitive trends in biosimilars and where effort and resources are focused. You'll find valuable insight from multiple perspectives.

To gain the very latest viewpoints, we carried out in-depth interviews with 11 senior experts within biologic or biosimilar businesses in the US, Europe, Korea and Russia. We discussed the most recent market developments and the key issues and challenges being addressed, including:

  • Prioritising and focusing: Markets are evolving at different rates and it's hard to keep up when there's so much going on. What do the experts say are the key developments over the last year, where have they occurred, and why are they important?
  • Defensive strategies and tactics: Explore the full range of biologics defences as well as the market responses to them. What has succeeded? How crucial is timing?
  • The rise of the hybrid: What is the impact of hybrid originator/biosimilar businesses and how have they changed market dynamics? Are partnerships having an adverse or favourable impact on biologic market dynamics and life cycle management strategies?
  • Patent pressure: Is courtroom confrontation still a viable (if expensive) strategy? Or are more conciliatory approaches to pricing, contracts and value-based offerings gaining traction and therefore worth considering?
  • Vulnerabilities and opportunities: Should you be on the offensive or the defensive? Is your life cycle management planning adopting a 'push' or a 'pull' approach? How do you plan to respond to regulatory change in different markets?

What to expect from this report

Now that biosimilars are here to stay, this report will get you up to speed quickly on the latest thinking, the most creative strategies and the most innovative approaches across the evolving biologics arena. Whether you're fighting to retain share or pushing hard to gain it, –it pays to stay abreast of the entire competitive landscape and build your knowledge before deciding what is likely to happen next.

Download Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era for a clear view of this rapidly changing market.

How did we do it?

  • We identified 13 current leading issues arising from biosimilar competition
  • We explored these via an average of 35 targeted questions put to each expert
  • Their responses provided 85 unique new insights
  • Insights are supported by 177 directly quoted comments plus an additional 44 sources

Example insight included in Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

"LCM strategies applied to date vary by product and portfolio mix, and in line with changes in the competitive landscape. The timing of these initiatives tends to vary as well, with some manufacturers building LCM strategies into drug development as early as Phase II trials. Market players emphasise the importance of strategies that bring value to an increasingly diversified marketplace. Given the growing presence of hybrid biologics-biosimilar companies, LCM will increasingly be about finding and implementing reciprocal competitive strategies that keep these parallel tracks in balance and drive customer segmentation."

Example quote included in Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

"I think we're seeing the same classic approaches. Move the goal posts so that there's a new presentation, a new preparation, a new indication, services around them. We see this sort of aggregation in products, services, indications and presentations come through. And in some markets, we see intellectual property come into play as well. A lot of the companies we've talked about have both innovator [biologics] and biosimilars. So if you look at the way the market is evolving, we're looking towards having that balance in the system."

The expert panel for Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

  • Caroline Boulliat, Biosimilar Business Unit Head, Amgen Immunology, UK
  • Rakesh Dixit, Vice President, Research & Development, and Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca), USA
  • Anonymous Director of Biologics Business, Top 20 pharma company, USA
  • Ian Henshaw, Head of Biosimilars, Biogen, UK
  • Florian Turk, Global Head, Payer Marketing, Sales and Engagement, Sandoz (Novartis), Germany
  • HoUng Kim, Head of the strategy and operations division, Celltrion Healthcare, South Korea
  • Roman Ivanov, Vice President, Research and Development, Biocad, Russia
  • Ildiko Aradi, Head, Clinical Development of Biologics, Gedeon Richter, Hungary
  • Christiane Hanke-Harloff, Director, Biotechnology Business Unit, Gedeon Richter, Germany
  • Anonymous Director of Biologics Business, Top 20 pharma company, USA
  • Anonymous Senior Drug Development Expert, Top 20 pharma company, Germany

Why buy now?

Both sides of the originator/biosimilar debate essentially want the same things: to protect and grow market share, to innovate, and to ultimately avoid an unseemly pricing scrum that creates long-term problems for everyone. Every biologic market participant must widen their perspective in order to compete effectively, and with hundreds of biosimilar products in the pipeline, competition is only going to intensify. Use this report to build your defences and ensure your biologics strategy is sustainable in the face of significant market disruption–no matter which side of the fence you are on.

Why FirstWord reports are different

  • 100% new content: You won't find old research presented as new. Guaranteed.
  • Opinions you need to hear: We only interview experts with current, relevant experience.
  • Professional researchers: The knowledge, experience and contacts to get the answers you need.